The crucial role of the chemokine CXCL13 has been demonstrated in non-small cell lung cancer and esophageal squamous cell carcinoma, while its predictive role in neoadjuvant immunotherapy for CRC remains to be explored (55, 56). Here, CXCL13 is linked to esophageal squamous cell carcinoma.